Accurate and Early Diagnosis of NSCLC Using Aberrant Fragmentomic Features of Circulating Cell-Free Mitochondrial DNA.

BACKGROUND Early differential diagnosis of benign and malignant lung diseases is a critical challenge in the clinical oncology of non-small cell lung cancer (NSCLC). We aim to develop a novel strategy utilizing circulating cell free mtDNA (ccf-mtDNA) fragmentomics for accurate and early diagnosis of NSCLC. METHODS We analyzed capture-based ccf-mtDNA sequencing data of 2,306 plasma samples from 1,357 NSCLC patients, 432 benign lung diseases (BLD) patients, and 517 healthy controls (HCs) obtained from three hospitals. Subsequently, using ccf-mtDNA fragmentomic features, we developed models for Differential diagnosis of Benign and Malignant lung diseases (DBM) and Early Diagnosis of NSCLC (EDL). RESULTS Our analysis revealed significantly aberrant fragmentomic features of ccf-mtDNA in NSCLC patients compared with those in BLD patients and HCs. Remarkably, the DBM model demonstrated remarkable capability to distinguish NSCLC from BLD, outperforming serum biomarkers with an AUC exceeding 0.9551 in three validation cohorts. Still, the DBM model exhibited superior diagnostic performance even for small nodules (< 1 cm), achieving an AUC of 0.9151. Moreover, the DBM model demonstrated precise clinical management ability of pulmonary lesions, thereby avoiding unnecessary invasive procedures in BLD patients and preventing delayed treatment in NSCLC patients. Furthermore, the EDL model demonstrated outstanding performance in detecting stage 0 - Ⅰ NSCLC, with an AUC exceeding 0.9759. CONCLUSIONS Our multicenter study provides a novel non-invasive approach using ccf-mtDNA fragmentomics for the differential diagnosis of benign and malignant lung diseases and early diagnosis of NSCLC, with potential applications in clinical decision-making in the management of NSCLC.